Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

SPECC1L regulates palate development downstream of IRF6
Hall, Everett G. , Wenger, Luke W., Wilson, Nathan R. , Undurty-Akella, Sraavya S, Standley, Jennifer , Augustine-Akpan, Eno-Abasi, Kousa, Youssef A. , Acevedo, Diana S., Goering, Jeremy P., Pitstick, Lenore, Natsume, Nagato , Paroya, Shahnawaz, Busch, Tamara , Mori, Akihiro , Schultz‐Rogers, Laura , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Kroc, Sarah A., Eshete, Mekonen , Bjork, Bryan C. , Suzuki, Satoshi , Murray, Jeffrey C. , Schutte, Brian C. , Butali, Azeez , Saadi, Irfan , Schultz-Rogers, Laura E, Babovic-Vuksanovic, Dusica, Wilson, Nathan R, Augustine‐Akpan, Eno‐Abasi, Ito, Masaaki, Mori, Akihiro, Imura, Hideto , Adeyemo, Wasiu Lanre

Mayo Clinic

Human Molecular Genetics | January 6, 2020 | Volume: 29 | Issue: 5 | Pages: 845-858

10.1093/hmg/ddaa002 | PMID 31943082 Get It

Abstract SPECC1L mutations have been identified in patients with rare atypical orofacial clefts and with syndromic cleft lip and/or palate (CL/P). These mutations cluster in the second coiled-coil and calponin homology domains of SPECC1L and severely affect the ability of SPECC1L to associate with microtubules. We previously showed that gene-trap knockout of Specc1l in mouse results in early embryonic lethality. We now present a truncation mutant mouse allele, Specc1lΔC510, that results in perinatal lethality. Specc1lΔC510/ΔC510 homozygotes showed abnormal palate rugae but did not show cleft palate. However, when crossed with a gene-trap allele, Specc1lcGT/ΔC510 compound heterozygotes showed a palate elevation delay with incompletely penetrant cleft palate. Specc1lcGT/ΔC510 embryos exhibit transient oral epithelial adhesions at E13.5, which may delay shelf elevation. Consistent with oral adhesions, we show periderm layer abnormalities, including ectopic apical expression of adherens junction markers, similar to Irf6 hypomorphic mutants and Arhgap29 heterozygotes. Indeed, SPECC1L expression is drastically reduced in Irf6 mutant palatal shelves. Finally, we wanted to determine if SPECC1L deficiency also contributed to non-syndromic (ns) CL/P. We sequenced 62 Caucasian, 89 Filipino, 90 Ethiopian, 90 Nigerian and 95 Japanese patients with nsCL/P and identified three rare coding variants (p.Ala86Thr, p.Met91Iso and p.Arg546Gln) in six individuals. These variants reside outside of SPECC1L coiled-coil domains and result in milder functional defects than variants associated with syndromic clefting. Together, our data indicate that palate elevation is sensitive to deficiency of SPECC1L dosage and function and that SPECC1L cytoskeletal protein functions downstream of IRF6 in palatogenesis.
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Keung, Emily Z. , Salazar, Ruth , Rodrigues-Canales, Jaime, Bolejack, Vanessa , Tine, Brian A. Van , Schuetze, Scott M. , Attia, Steven , Riedel, Richard F. , Hu, James , Okuno, Scott H. , Priebat, Dennis A., Movva, Sujana , Davis, Lara E. , Wang, Wei‐Lien , Wargo, Jennifer A. , Tawbi, Hussein A. , Bolejack, Vanessa , Van Tine, Brian A , Schuetze, Scott M , Riedel, Richard F , Okuno, Scott , Davis, Lara E , Reed, Damon R , Reuben, Alexandre , Lazar, Alexander J , Burgess, Melissa , Parra, Edwin Roger , Reed, Damon R. , Roland, Christina Lynn , Reinke, Denise K. , Lazar, Alexander J.

Mayo Clinic

Clinical Cancer Research | January 3, 2020 | Volume: 26 | Issue: 6 | Pages: 1258-1266

10.1158/1078-0432.ccr-19-1824 | PMID 31900276 Get It

Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). We sought to determine whether we can identify immune features that correlate with clinical outcomes from tumor tissues obtained pre- and on-treatment. Patients and Methods: Pretreatment (n = 78) and 8-week on-treatment (n = 68) tumor biopsies were stained for PD-L1 and multiplex immunofluorescence panels. The density of positive cells was quantified to determine associations with anti–PD-1 response. Results: Patients that responded to pembrolizumab were more likely to have higher densities of activated T cells (CD8+ CD3+ PD-1+) and increased percentage of tumor-associated macrophages (TAM) expressing PD-L1 pre-treatment compared with non-responders. Pre-treatment tumors from responders also exhibited higher densities of effector memory cytotoxic T cells and regulatory T cells compared with non-responders. In addition, higher density of cytotoxic tumor-infiltrating T cells at baseline correlated with a better progression-free survival (PFS). Conclusions: We show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS. Our findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti–PD-1 therapy in specific advanced sarcomas. Efforts to confirm the activity of pembrolizumab in an expansion cohort of patients with UPS/DDLPS are underway.
Detection of Enzootic Babesiosis in Baboons (Papio cynocephalus) and Phylogenetic Evidence Supporting Synonymy of the GeneraEntopolypoidesandBabesia
Bronsdon, Melinda A., Homer, Mary J., Magera, Jennifer M. H., Harrison, Carol , Andrews, Robert G., Bielitzki, Joseph T., Emerson, Carol L., Persing, David H., Fritsche, Thomas R., Harrison, Carol

Mayo Clinic

Journal of Clinical Microbiology | December 31, 2019 | Volume: 37 | Issue: 5 | Pages: 1548-1553

10.1128/jcm.37.5.1548-1553.1999 | PMID 10203519 Get It

ABSTRACTBlood smear evaluation of two baboons (Papio cynocephalus) experiencing acute hemolytic crises following experimental stem cell transplantation revealed numerous intraerythrocytic organisms typical of the genusBabesia. Both animals had received whole-blood transfusions from two baboon donors, one of which was subsequently found to display rare trophozoites ofEntopolypoides macaci. An investigation was then undertaken to determine the prevalence of hematozoa in baboons held in our primate colony and to determine the relationship, if any, between the involved species. Analysis of thick and thin blood films from 65 healthy baboons (23 originating from our breeding facility, 26 originating from an out-of-state breeding facility, and 16 imported from Africa) for hematozoa revealed rareE. macaciparasites in 31%, with respective prevalences of 39, 35, and 12%. Phylogenetic analysis of nuclear small-subunit rRNA gene sequences amplified from peripheral blood of a baboon chronically infected withE. macacidemonstrated this parasite to be most closely related toBabesia microti(97.9% sequence similarity); sera from infected animals did not react in indirect fluorescent-antibody tests withBabesia microtiantigen, however, suggesting that they represent different species. These results support an emerging view that the genusEntopolypoidesMayer 1933 is synonymous with that of the genusBabesiaStarcovici 1893 and that the morphological variation noted among intracellular forms is a function of alteration in host immune status. The presence of an underrecognized, but highly enzootic,Babesiasp. in baboons may result in substantial, unanticipated impact on research programs. The similarity of this parasite to the known human pathogenB. microtimay also pose risks to humans undergoing xenotransplantation, mandating effective screening of donor animals.
Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency
Runolfsdottir, Hrafnhildur L. , Agustsdottir, Inger M. Sch., Indridason, Ólafur S. , Li, Jennifer , Dao, Myriam , Knebelmann, Bertrand , Milliner, Dawn S. , Pálsson, Runólfur , Edvardsson, Vidar Orn

Mayo Clinic

Transplantation | December 27, 2019 | Volume: 104 | Issue: 10 | Pages: 2120-2128

10.1097/tp.0000000000003088 | PMID 31880754 Get It

Background. Adenine phosphoribosyltransferase (APRT) deficiency is a rare, hereditary cause of kidney stones and chronic kidney disease (CKD) which is characterized by 2,8-dihydroxyadenine renal parenchymal crystal deposition. The aim of this study was to examine outcomes of kidney transplantation in APRT deficiency patients. Methods. Included were 13 patients in the APRT Deficiency Registry of the Rare Kidney Stone Consortium, 2 from Westmead Hospital in Sydney, Australia, and 2 from Necker Hospital in Paris, France. The CKD-EPI and CKiD equations were used to calculate glomerular filtration rate estimates. Allograft survival was analyzed employing the Kaplan-Meier method. The Wilcoxon-Mann-Whitney test was used to compare alllograft outcomes according to xanthine oxidoreductase (XOR) inhibitor treatment status at transplantation. Results. Seventeen patients (9 females) received 22 kidney transplants. Age at first transplantation was 47.2 (14.9–67.0) years. Ten patients received XOR inhibitor therapy pretransplant (11 allografts), while 8 patients did not receive such treatment before transplantation (11 allografts). Two-year allograft survival was 91% and 55% in the 2 groups, respectively (P = 0.16). The median (range) estimated glomerular filtration rate at 2 years posttransplant was 61.3 (24.0–90.0) mL/min/1.73 m2 when XOR inhibitor therapy was initiated before transplantation, and 16.2 (10.0–39.0) mL/min/1.73 m2 (P = 0.009) when such treatment was not administered pretransplant. Conclusions. Kidney allograft outcomes are good in APRT deficiency patients beginning XOR inhibitor therapy pretransplant. Delay in such treatment is a major cause of premature graft loss in these patients. Increased awareness among clinicians is imperative, promoting early diagnosis of APRT deficiency and pharmacotherapy initiation before kidney transplantation.
Understanding Diverse Perspectives on Genetic Research Through Focus Group Talk
Ridgeway, Jennifer L. , Albertie, Monica, Pantoja, Elizabeth, Prescott, Darin, Zhu, Xuan , Breitkopf, Carmen Radecki , Ridgeway, Jennifer L

Mayo Clinic

International Journal of Qualitative Methods | December 27, 2019 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/1609406919892476 Get It

While genetic research (GR) is fueling discoveries in fields like precision medicine, there is a growing concern that underrepresentation of racial and ethnic populations in GR will limit access to its benefits and subsequently worsen health disparities. This study aimed to understand GR perceptions among members from underrepresented communities by studying discourse and language use in focus group discussions. Nine focus groups were conducted with adults from three populations: African American, Hispanic/Latino, and Native American; 53 women and 15 men participated. Data were analyzed using methods of discourse and content analysis. Discourse analysis highlighted how conceptualization of science and family—rooted in historical experiences—can influence views on GR risks and benefits to self and others. The use of focus group discourse in particular provided an opportunity for group sense making around the science and ethics of GR. Content analysis highlighted differences between the language use of focus group moderators, who spoke about scientific discovery and research oversight, and that of participants, whose talk highlighted ancestral bloodline, personal risk, and ethical concerns. The findings can inform efforts to bolster GR participation, including recruitment and educational campaigns. However, they also challenge researchers to consider areas of discordance between their own and community members’ conceptualization of the risks and benefits of GR participation, including the notion of future and family benefit.
DDIS-18. NANOCELL-MEDIATED DELIVERY OF MIR-34A COUNTERACTS TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA
Khan, Muhammad Babar , Ruggieri, Rosamaria, MacDiarmid, Jennifer A. , Brahmbhatt, Himanshu , Boockvar, John A. , Symons, Marc , Tran, Nhan L. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | December 23, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi66-vi67

10.1093/neuonc/noz175.269 Get It

Abstract BACKGROUND Glioblastomas show marked intra- and inter-tumor heterogeneity and are strongly resistant to both radio- and chemo-therapy, which are standard therapeutic modalities for this tumor. MicroRNAs (miRNAs) have the potential to serve as effective therapeutics for glioblastoma as they modulate the activity of multiple signaling pathways. METHODS Glioblastoma cultures were transfected with miR-34a or control miRNA mimics to assess biological function and therapeutic potential in vitro. miR-34a was packaged into bacterially-derived nanocells and administered intravenously for delivery to orthotopic patient-derived glioblastoma xenografts in mice. RESULTS Overexpression of miR-34a strongly reduced the activation status of the three core signaling networks that have been found to be deregulated in the vast majority of glioblastoma tumors, the receptor tyrosine kinase, p53 and Rb networks. miR-34a transfection also inhibited the survival of multiple established glioblastoma cell lines as well as primary patient-derived xenograft cultures representing the proneural, mesenchymal and classical subtypes. Transfection of miR-34a synergized with temozolomide (TMZ) in in vitro cultures of glioblastoma cells with primary TMZ sensitivity, primary TMZ resistance and acquired TMZ resistance. Intravenous administration of bacterially-derived nanocells carrying miR-34a strongly enhanced TMZ sensitivity in an orthotopic patient-derived xenograft mouse model of glioblastoma. CONCLUSIONS miR-34a strongly sensitizes a wide range of glioblastoma cell cultures to TMZ, suggesting that combination therapy of TMZ with miR-34a may serve as a novel therapeutic approach for the treatment of glioblastoma tumors. Bacterially-derived nanocells are an effective vehicle for the delivery of miR-34a to glioblastoma tumors.
Impact of Aspirin on Takotsubo Syndrome: A Propensity Score-Based Analysis of the InterTAK Registry
Gili, Sebastiano , Bertaina, Maurizio , Iannaccone, Mario , Cammann, Victoria L. , Vece, Davide Di , Saglietto, Andrea , Szawan, Konrad A. , Frangieh, Antonio H. , Boffini, Beatrice, Annaratone, Margherita, Sarcon, Annahita, Levinson, Rena A. , Franke, Jennifer , Napp, L. Christian , Münzel, Thomas , Knorr, Maike, Heiner, Susanne, Katus, Hugo A. , Burgdorf, Christof , Tschöpe, Carsten , Pieske, Burkert , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Köenig, Wolfgang , Rottbauer, Wolfgang , Said, Samir M., Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Airaksinen, Juhani , Opolski, Grzegorz , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Franz, Wolfgang M., Empen, Klaus , Felix, Stephan B. , El‐Battrawy, Ibrahim , Akın, İbrahim , Borggrefe, Martin, Kozel, Martin , Widimský, Petr , Gilyarova, Ekaterina, Gilyarov, Mikhail , Biondi‐Zoccai, Giuseppe , Winchester, David E. , Ukena, Christian , Prasad, Abhiram , Böhm, Michael , Bossone, Eduardo , Citro, Rodolfo , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , D’Ascenzo, Fabrizio , Kato, Ken , Jaguszewski, Miłosz , Noutsias, Michel , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Hasenfuß, Gerd , Braun-Dullaeus, Ruediger Christian , Kaiser, Christoph A. , Crea, Filippo , Dichtl, Wolfgang , Delmas, Clément , Lairez, Olivier , Horowitz, John D. , Toušek, Petr , Shilova, Alexandra S. , Neuhaus, Michael, Bax, Jeroen J. , Mario, Carlo Di , Gasparini, Mauro , Ruschitzka, Frank T. , Rinaldi, Mauro , Ferrari, Gaetano Maria De

Mayo Clinic

European Journal of Heart Failure | December 21, 2019 | Volume: 22 | Issue: 2 | Pages: 330-337

10.1002/ejhf.1698 | PMID 31863563 Get It

Abstract Aims The aim of the present study was to investigate the impact of aspirin on prognosis in takotsubo syndrome (TTS). Methods and results Patients from the International Takotsubo (InterTAK) Registry were categorized into two groups based on aspirin prescription at discharge. A comparison of clinical outcomes between groups was performed using an adjusted analysis with propensity score (PS) stratification; results from the unadjusted analysis were also reported to note the effect of the PS adjustment. Major adverse cardiac and cerebrovascular events (MACCE: a composite of death, myocardial infarction, TTS recurrence, stroke or transient ischaemic attack) were assessed at 30-day and 5-year follow-up. A total of 1533 TTS patients with known status regarding aspirin prescription at discharge were included. According to the adjusted analysis based on PS stratification, aspirin was not associated with a lower hazard of MACCE at 30-day [hazard ratio (HR) 1.24, 95% confidence interval (CI) 0.50–3.04, P = 0.64] or 5-year follow-up (HR 1.11, 95% CI 0.78–1.58, P = 0.58). These results were confirmed by sensitivity analyses performed with alternative PS-based methods, i.e. covariate adjustment and inverse probability of treatment weighting. Conclusion In the present study, no association was found between aspirin use in TTS patients and a reduced risk of MACCE at 30-day and 5-year follow-up. These findings should be confirmed in adequately powered randomized controlled trials. ClinicalTrials.gov Identifier: NCT01947621.
Association of Intracranial Atherosclerotic Disease With Brain β-Amyloid Deposition
Wong, Dean F. , Wagenknecht, Lynne E. , Hughes, Timothy M. , Qiao, Ye , Dearborn, Jennifer L. , Wasserman, Bruce A. , Gottesman, Rebecca F. , Mosley, Thomas H. , Knopman, David S. , Hao, Qing

Mayo Clinic

JAMA Neurology | December 20, 2019 | Volume: 77 | Issue: 3 | Pages: 350

10.1001/jamaneurol.2019.4339 | PMID 31860001 Get It

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors
Howe, James R. , Merchant, Nipun B. , Conrad, Claudius , Keutgen, Xavier M. , Hallet, Julie , Drebin, Jeffrey A. , Minter, Rebecca M., Lairmore, Terry C., Tseng, Jennifer F. , Zeh, Herbert J. , Libutti, Steven K. , Singh, Gagandeep , Lee, Jeffrey E. , Kim, Michelle K. , Menda, Yusuf , Hálfdánarson, Þorvarður R. , Chan, Jennifer A. , Pommier, Rodney F. , Kim, Michelle Kang , Halfdanarson, Thorvardur R , Howe, James R , Menda, Yusuf , Lee, Jeffrey E., Hope, Thomas A.

Mayo Clinic

Pancreas | December 19, 2019 | Volume: 49 | Issue: 1 | Pages: 1-33

10.1097/mpa.0000000000001454 | PMID 31856076 Get It

Abstract This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the surgical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The group reviewed a series of questions of specific interest to surgeons taking care of patients with pancreatic neuroendocrine tumors, and for each, the available literature was reviewed. What follows are these reviews for each question followed by recommendations of the panel.
Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study
James, Spencer L , Lucchesi, Lydia R , Bisignano, Catherine, Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Henry, Nathaniel J , McCracken, Darrah, Sylte, Dillon O , Ahmadi, Alireza , Alahdab, Fares , Alipour, Vahid , Andualem, Zewudu , Arabloo, Jalal , Badiye, Ashish , Bagherzadeh, Mojtaba , Banstola, Amrit , Bärnighausen, Till , Barzegar, Akbar , Bayati, Mohsen , Bhaumik, Soumyadeep , Bijani, Ali , Bukhman, Gene , Carvalho, Félix , Crowe, Christopher S. , Dalal, Koustuv , Nasab, Mostafa Dianati, Endries, Aman Yesuf , Fernandes, Eduarda , Fischer, Florian , Fukumoto, Takeshi, Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gilani, Syed Amir , Haagsma, Juanita A., Hostiuc, Sorin , Househ, Mowafa , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Kahsay, Amaha , Kapoor, Neeti , Kasaeian, Amir , Khader, Yousef , Khalil, Ibrahim A, Khan, Ejaz Ahmad , Khazaee-Pool, Maryam , Kokubo, Yoshihiro , Madadin, Mohammed , Majdán, Marek , Maled, Venkatesh , Manafi, Navid , Manafi, Ali, Mangalam, Srikanth , Massenburg, Benjamin B. , Meles, Hagazi Gebre , Menezes, Ritesh G. , Meretoja, Tuomo J , Miazgowski, Bartosz , Miller, Ted R. , Mohammadian-Hafshejani, Abdollah , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Cuong Tat , Nixon, Molly R, Olagunju, Andrew T , Olagunju, Tinuke O , Padubidri, Jagadish Rao , Polinder, Suzanne , Rabiee, Navid , Rahimi‐Movaghar, Vafa , Rawaf, David Laith , Rezapour, Aziz , Rickard, Jennifer , Roro, Elias Merdassa , Roy, Nobhojit , Salamati, Payman, Samy, Abdallah M , Satpathy, Maheswar , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shigematsu, Mika, Tohidinik, Hamid Reza , Valdéz, Pascual , Wijeratne, Tissa , Yisma, Engida , Zaidi, Zoubida , Zhang, Zhi-Jiang, Hay, Simon I , Mokdad, Ali H. , Dianatinasab, Mostafa , Wijeratne, T , Roberts, Nicholas L S , Ahmed, Muktar Beshir , Antonio, Carl Abelardo T. , Daryani, Ahmad , Do, Hoa , Do, Huyen Phuc , Filip, Irina , Fukumoto, Takeshi, Hamidi, Samer , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Khalil, Ibrahim A, Lopez, Alan D , Malekzadeh, Reza , Mohammadpourhodki, Reza , Morrison, Shane D. , Nguyen, Trang Huyen , Rabiee, Mohammad , Radfar, Amir , Rawaf, Salman , Safari‐Faramani, Roya , Salamati, Payman, Sepanlou, Sadaf Ghajarieh , Soheili, Amin , Stokes, Mark Andrew , Tran, Bach Xuan , Zamani, Mohammad , Zhang, Zhi‐Jiang , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | December 19, 2019 | Volume: 26 | Issue: Suppl 2 | Pages: i36-i45

10.1136/injuryprev-2019-043299 | PMID 31857422 Get It

Background Past research has shown how fires, heat and hot substances are important causes of health loss globally. Detailed estimates of the morbidity and mortality from these injuries could help drive preventative measures and improved access to care. Methods We used the Global Burden of Disease 2017 framework to produce three main results. First, we produced results on incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years from 1990 to 2017 for 195 countries and territories. Second, we analysed these results to measure mortality-to-incidence ratios by location. Third, we reported the measures above in terms of the cause of fire, heat and hot substances and the types of bodily injuries that result. Results Globally, there were 8 991 468 (7 481 218 to 10 740 897) new fire, heat and hot substance injuries in 2017 with 120 632 (101 630 to 129 383) deaths. At the global level, the age-standardised mortality caused by fire, heat and hot substances significantly declined from 1990 to 2017, but regionally there was variability in age-standardised incidence with some regions experiencing an increase (eg, Southern Latin America) and others experiencing a significant decrease (eg, High-income North America). Conclusions The incidence and mortality of injuries that result from fire, heat and hot substances affect every region of the world but are most concentrated in middle and lower income areas. More resources should be invested in measuring these injuries as well as in improving infrastructure, advancing safety measures and ensuring access to care.